Girard Partners’s Sage Therapeutics SAGE Stock Holding History

Girard Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-430	Closed	-$60K	–	697
2018 Q3	$60K	Buy	+430	New	+$66.4K	0.01%	423

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Girard Partners's SAGE Position: Q4 2018 in Review

Girard Partners sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 430 shares — an estimated $60K sold.

Girard Partners first reported a position in SAGE in Q3 2018 and held it in 1 quarter. The position peaked at $60K in Q3 2018. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

Girard Partners reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 430 Sage Therapeutics shares in Q4 2018, an estimated $60K.
Girard Partners first reported a position in Sage Therapeutics in Q3 2018 and held it in 1 quarter.
Girard Partners's Sage Therapeutics position peaked at $60K in Q3 2018.
248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.